Eksigent Continues European Expansion with new Distribution Agreement in Benelux
News Mar 07, 2007
Eksigent has announced a new distribution agreement with Separations Analytical Instruments BV, based in The Netherlands. The agreement covers sales of Eksigent’s NanoLC™ HPLC product line in the Benelux region.
“Our NanoLC platform for proteomics applications has been well received in the U.S. biotech and pharmaceutical industries as well as the academic community,” commented David Weber, Eksigent’s President and CEO. “We have now expanded our marketing and management staff and we’re well-positioned to serve the European academic, biotech and pharmaceutical markets.”
Separations Analytical Instruments, founded in 1989, specializes in sales and service of HPLC and online SPE systems, representing a range of US and European-based manufacturers. The company serves pharmaceutical, life science and environmental customers with special emphasis on high-throughput applications.
“We are delighted to represent the Eksigent NanoLC product line,” commented Rein Reitsma, Sales Manager for Separations Analytical. “Eksigent systems are the most innovative and reliable NanoLC products we can offer to our customers in the Benelux region.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.